Mass spectrometry / NMR

Kerstin Pohl, Senior Global Marketing Manager, Gene Therapy & Nucleic Acid at SCIEX, looks at the application of liquid chromatography-mass spectrometry for analysing host cell proteins. Gene-based therapeutics and vaccines hold immense potential for more efficient and personalised treatment and prevention of complex diseases. However, the increased complexity and diversity involved in the development and […]

This paid-for advertorial by SCIEX appeared in DDW Volume 24 – Issue 2, Spring 2023 Imagine having the ability to consistently identify metabolic soft spots from an experiment that uses liquid chromatography coupled to mass spectrometry (LC-MS), reducing the need for additional safety testing in the drug discovery phase. Metabolite identification A key step in the drug […]

DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick, about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. At the beginning of 2023, proteomics company Nautilus Biotechnology announced a partnership with the Translational Genomics Research Institute (TGen), to study […]

This is the latest episode of the free DDW podcast, “Mass spectrometry and CRISPR are pillars of drug discovery”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “How ASMS offers more than seeing what sticks” and “CRISPR screening in the third dimension”. In the first […]

Newly published discoveries have revealed possibilities for the treatment of cancer by targeting tumour-associated macrophages (TAMs) in the tumour microenvironment (TME).  The founding scientists behind Edinburgh-based Macomics, Dr Luca Cassetta and Professor Jeff Pollard, detail the seminal discoveries in macrophage biology over the past 50 years in a major Perspectives review in Nature Reviews Cancer.  […]

Arndt Asperger, Senior Applications Scientist, Bruker Daltonics and Meike Hamester, Vice President Label-Free Technologies, Bruker Daltonics, examine how challenges in mass spectrometry for high-throughput screening can be overcome using a label-free approach.   Mass spectrometry is inherently appealing for high-throughput screening (HTS), because it avoids certain drawbacks of label-based assays, but long-standing limitations of cost per sample, […]

Download the new App Note from Analytik Jena to find out more about: The detection of lipid changes in microglia cells in generating therapeutic approach towards neuroinflammation diseases The application of label-free matrix-assisted laser desorption/ionisation (MALDI) MS cell fingerprinting workflows or cellular assays capable of characterising drug off-target responses with high throughput sample preparation done […]

By Idlir Liko, Kleitos Sokratous & Miguel Silva at OMass Therapeutics Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s work, including her recent publication in Nature, highlights how native mass spectrometry offers a new way to discover therapeutics against inadequately drugged or intractable […]

In this article, Professor Zheng-Zhu (Principal Investigator and Director of Metabolomics Research Center at the Shanghai Institute of Organic Chemistry) and Lucy Woods (Business Unit Manager for Phenomics and Metabolomics at Bruker Daltonics), summarise the most important configurations and options for partnering IMS–MS with liquid chromatography (LC) and show how this approach could revolutionise metabolome […]

In this article, Komal Kedia (Senior Scientist at Merck), Rena Zhang (Senior Scientist at Merck), Weixun Wang (Senior Scientist at Merck), Kevin Bateman (Scientific Associate VP at Merck) and Kelly Moser (Applications Manager at MOBILion Systems) show how ganglioside isomers with suspected roles in neurodegenerative diseases can be separated on the basis of their ion […]